Esperion Therapeutics, Inc.
ESPRNASDAQHealthcare● Active
$3.14
+$0.01(+0.32%)
Market Cap$652833399
P/E Ratio—
52W High$4.18
52W Low$0.95
Esperion Therapeutics, Inc. (ESPR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ESPR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.10
Est. -$0.04 · -150.0%
Revenue
$0.08B
Est. $0.08B · -5.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
ESPR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.06
Rev. $0.47B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.06
Rev. Est.$0.47B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.02 | — | — | — | $0.09B | — |
| ▼ Q2 FY2026 | May 8, 2026 | -$0.04 | -$0.10 | -150.0% | $0.08B | $0.08B | -5.2% |
| ▼ Q1 FY2026 | Mar 10, 2026 | $0.23 | $0.22 | -4.3% | $0.17B | $0.17B | +1.2% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.09 | -$0.16 | -77.8% | $0.09B | $0.17B | -47.1% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.17 | -$0.02 | +88.2% | $0.08B | $0.08B | -0.1% |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.18 | -$0.21 | -16.7% | $0.06B | $0.06B | +6.2% |
| ▲ Q1 FY2025 | Mar 4, 2025 | -$0.14 | -$0.10 | +28.6% | $0.07B | $0.05B | +33.7% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.14 | -$0.15 | -7.1% | $0.05B | $0.06B | -16.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
-$0.10
EPS Est.
-$0.04
EPS Surpr.
-150.0%
Revenue
$0.08B
Q1 FY2026
Mar 10, 2026Miss
EPS Actual
$0.22
EPS Est.
$0.23
EPS Surpr.
-4.3%
Revenue
$0.17B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.16
EPS Est.
-$0.09
EPS Surpr.
-77.8%
Revenue
$0.09B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.17
EPS Surpr.
+88.2%
Revenue
$0.08B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.18
EPS Surpr.
-16.7%
Revenue
$0.06B
Q1 FY2025
Mar 4, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.14
EPS Surpr.
+28.6%
Revenue
$0.07B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.15
EPS Est.
-$0.14
EPS Surpr.
-7.1%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.09 | $0.09 | $0.09 | 1 |
| Q3 FY2027 | $0.07 | $0.07 | $0.07 | 1 |
| Q2 FY2027 | $0.06 | $0.06 | $0.06 | 1 |
| Q1 FY2027 | $0.03 | $0.03 | $0.03 | 1 |
| Q4 FY2026 | $0.02 | $0.02 | $0.02 | 1 |
| Q3 FY2026 | $-0.00 | $0.00 | $0.00 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -150.0% | $3.14 | $3.14 | +0.00% |
| ▼ Q1 FY2026 | Mar 10, 2026 | -4.3% | $3.04 | $2.70 | -11.18% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -77.8% | $2.94 | $2.50 | -14.97% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +88.2% | $1.49 | $1.62 | +8.72% |
| ▼ Q2 FY2025 | May 6, 2025 | -16.7% | $1.05 | $0.98 | -7.10% |
| ▲ Q1 FY2025 | Mar 4, 2025 | +28.6% | $1.58 | $1.77 | +12.03% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -7.1% | $2.21 | $2.11 | -4.52% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +66.7% | $2.02 | $1.84 | -8.91% |
Q2 FY2026+0.00%
Report Date
May 8, 2026
EPS Beat/Miss
-150.0%
Price Before
$3.14
Price After
$3.14
Q1 FY2026-11.18%
Report Date
Mar 10, 2026
EPS Beat/Miss
-4.3%
Price Before
$3.04
Price After
$2.70
Q4 FY2025-14.97%
Report Date
Nov 6, 2025
EPS Beat/Miss
-77.8%
Price Before
$2.94
Price After
$2.50
Q3 FY2025+8.72%
Report Date
Aug 5, 2025
EPS Beat/Miss
+88.2%
Price Before
$1.49
Price After
$1.62
Q2 FY2025-7.10%
Report Date
May 6, 2025
EPS Beat/Miss
-16.7%
Price Before
$1.05
Price After
$0.98
Q1 FY2025+12.03%
Report Date
Mar 4, 2025
EPS Beat/Miss
+28.6%
Price Before
$1.58
Price After
$1.77
Q4 FY2024-4.52%
Report Date
Nov 7, 2024
EPS Beat/Miss
-7.1%
Price Before
$2.21
Price After
$2.11
Q3 FY2024-8.91%
Report Date
Aug 12, 2024
EPS Beat/Miss
+66.7%
Price Before
$2.02
Price After
$1.84
Avg Beat Reaction+3.95%
Avg Miss Reaction-7.55%
Beat Rate3 / 8 quarters
Largest Move-14.97% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ESPR ends December
Esperion Therapeutics, Inc. (ESPR) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.10 — missing the analyst consensus of $-0.04 by -150.0%. The next ESPR earnings date is expected around September 1, 2026.
Each quarter, investors track ESPR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ESPR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ESPR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ESPR earnings · 5 questionsEsperion Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ESPR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ESPR historically reports after market close (AMC).
ESPR earnings datewhen is ESPR earningsESPR next earnings datewhen does ESPR report earningsESPR earnings calendar
▸ Source: FMP · Esperion Therapeutics, Inc. SEC filings · US GAAP · Esperion Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026